Medical Technology Shares Gain: Clever Culture, Pacific Edge and Nova Eye Medical Rise

Sonal Goyal

13 November 2026 02:46 PM AEDT

Medical Technology Shares Gain: Clever Culture, Pacific Edge and Nova Eye Medical Rise

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Clever Culture Systems (ASX:CC5), Pacific Edge (ASX:PEB) and Nova Eye Medical (ASX:EYE) all traded higher during the 13 November 2026 session.
Clever Culture shares rose 7.14%, Pacific Edge 6.98% and Nova Eye Medical 6.45%.
The three companies reported Medicare coverage, a funding package and quarterly sales growth in their latest updates.

During the Trading session on 13 November 2026, Clever Culture Systems Ltd (ASX:CC5) shares were trading at $0.015, up 7.14%, Pacific Edge (ASX:PEB) shares were at $0.23, up 6.98%, and Nova Eye Medical Ltd (ASX:EYE) shares were at $0.165, up 6.45%. The S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT over the same session. All three are healthcare technology companies with products sold into clinical or industrial settings.

Clever Culture Systems (ASX:CC5)

Clever Culture Systems is an Adelaide-based developer of AI microbiology automation. Its announcement dated 3 November 2026 said it has received commitments for a $2.6 million funding package for APAS Revolution, a benchtop system for smaller sterile drug manufacturers. The package includes a targeted $1.0 million Capital raise and a $1.6 million Unsecured Loan due on 30 November 2027. The company estimates the change expands the total addressable market for its technology by about 50% to $4.3 billion.

Pacific Edge (ASX:PEB)

Pacific Edge is a cancer diagnostics company based in Dunedin, New Zealand, listed on the NZX and the ASX. Its announcement dated 6 November 2026 said the final Local Coverage Determination confirming Medicare coverage for Cxbladder Triage and Triage Plus has been published. The determination is scheduled to take effect on 20 December 2026, and the company estimates about 1.14 million testing opportunities a year for intermediate-risk microhaematuria patients.

Nova Eye Medical (ASX:EYE)

Nova Eye Medical develops ophthalmic devices for the interventional glaucoma market. Its quarterly report, released on 27 October 2026, reported sales of US$6.3 million in the September quarter, up 30% on the prior corresponding period, and trailing annual Revenue of US$25.1 million. The company reported positive EBITDA for the quarter, an operating cash inflow of A$0.5 million and Liquidity of A$4.1 million, and confirmed its FY27 guidance.

Final Word

The three companies have each reported a development in their latest updates, from a regulatory decision to a funding package and a quarter of sales growth. Their next updates will show how these developments progress.

FAQs

Q: Which of the three companies reported Medicare coverage?

A: Pacific Edge (ASX:PEB) reported that the final determination confirming Medicare coverage for Cxbladder Triage and Triage Plus has been published.

Q: How much sales did Nova Eye Medical report for the quarter?

A: Sales were US$6.3 million, up 30% on the prior corresponding period.

Q: What is the funding package at Clever Culture Systems?

A: It is a $2.6 million package, comprising a targeted $1.0 million capital raise and a $1.6 million unsecured loan.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.